Top Suppliers:I want be here


432037-57-5

432037-57-5 structure
432037-57-5 structure
  • Name: Teglarinad chloride
  • Chemical Name: [4-[[N'-[6-(4-chlorophenoxy)hexyl]-N-cyanocarbamimidoyl]amino]pyridin-1-ium-1-yl]methyl 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl carbonate,chloride
  • CAS Number: 432037-57-5
  • Molecular Formula: C30H43Cl2N5O8
  • Molecular Weight: 672.59700
  • Catalog: Pharmaceutical intermediate Heterocyclic compound Pyridine compound Cyanopyridine
  • Create Date: 2019-01-25 22:47:13
  • Modify Date: 2024-04-06 12:01:04
  • Teglarinad chloride (GMX1777) is a prodrug of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis[1][2].

Name [4-[[N'-[6-(4-chlorophenoxy)hexyl]-N-cyanocarbamimidoyl]amino]pyridin-1-ium-1-yl]methyl 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethyl carbonate,chloride
Synonyms GMX1777
UNII-D6V5QYX9MZ
Teglarinad chloride
Description Teglarinad chloride (GMX1777) is a prodrug of GMX1778 (a nicotinamide phosphoribosyl transferase inhibitor). Teglarinad chloride exhibits antitumor activity in mice can be attributed to inhibition of NAMPT. Teglarinad chloride also enhances radiation efficacy, mediated by interference with DNA repair and antiangiogenesis[1][2].
Related Catalog
In Vivo GMX1777 (75 mg/kg; 24 h intravenous infusion) causes tumor regression in the IM-9 model, a small-cell lung cancer (SHP-77) model, and a colon carcinoma (HCT-116) model[2]. GMX1777 (50-100 mg/kg/d, i.m. for 5 d) with or without local tumor radiotherapy is effective for both FaDu and C666-1 tumors in vivo[1]. GMX1777 (25-400 mg/kg; 24 h intravenous infusion) is quickly converted to GMX1778 in plasma of mice with a half-life of GMX1777 less than 0.7 h[2]. Animal Model: CB17 SCID/SCID female mice bearing subcutaneous IM-9 multiple myeloma tumors[2] Dosage: 18.75, 35, 75 mg/kg Administration: A 24 h intravenous infusion Result: Induced a nearly complete regression of the tumors and a significant tumor growth delay at the dose of 75mg/kg. Reduced IM-9 tumor growth moderately At 37.5mg/kg.
References

[1]. Kato H, et, al. Efficacy of combining GMX1777 with radiation therapy for human head and neck carcinoma. Clin Cancer Res. 2010 Feb 1;16(3):898-911.

[2]. Beauparlant P, et, al. Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777. Anticancer Drugs. 2009 Jun;20(5):346-54.

Melting Point 158-159ºC
Molecular Formula C30H43Cl2N5O8
Molecular Weight 672.59700
Exact Mass 671.24900
PSA 147.15000
LogP 5.10808
Hazard Codes Xi